Blow for Sanofi as tusamitamab ravtansine misses Phase III goal

21 December 2023

French pharma major Sanofi (Euronext: SAN) today revealed it is discontinuing the global clinical development program of its antibody-drug conjugate (ADC) candidate tusamitamab ravtansine.

The decision is based on the outcome of a prespecified interim analysis of the Phase III CARMEN-LC03 trial evaluating tusamitamab ravtansine as monotherapy compared to docetaxel in previously treated patients with metastatic non-squamous (NSq) non-small cell lung cancer (NSCLC) whose tumors express high levels of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).

Sanofi had previously pinned its hopes on tusamitamab ravtansine as a major component of its comparatively sparse ADC pipeline after gaining a license to develop four molecules including tusamitamab in 2017, in an upfront $30 million deal with Massachusetts, USA-based ADC specialist ImmunoGen (Nasdaq: IMGN).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK